← All trials
NCT03243851
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 21, 2016
- Primary completion
- Dec 31, 2018
- Completion date
- Dec 31, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 108
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Catholic University of KoreaLead sponsor
- Ajou UniversityCollaborator
- Seoul National UniversityCollaborator
- Yonsei UniversityCollaborator
- Konkuk UniversityCollaborator
- University of UlsanCollaborator
- Sungkyunkwan UniversityCollaborator
- Catholic University of KoreaCollaborator
- Catholic University of KoreaSponsor investigator
- Catholic University of KoreaOverall official - principal investigator
- National Cancer Center, KoreaCollaborator
- Chonnam National UniversityCollaborator
- Incheon St.Mary's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.